A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage-Reference-Cited by-同舟云学术

A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage

Published:2018-03-16 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Ladds Marcus J. G. W.,van Leeuwen Ingeborg M. M.,Drummond Catherine J.,Chu Su,Healy Alan R.,Popova Gergana,Pastor Fernández Andrés,Mollick Tanzina,Darekar Suhas,Sedimbi Saikiran K.,Nekulova Marta,Sachweh Marijke C. C.,Campbell Johanna,Higgins Maureen,Tuck Chloe,Popa Mihaela,Safont Mireia Mayoral,Gelebart Pascal,Fandalyuk Zinayida,Thompson Alastair M.,Svensson Richard,Gustavsson Anna-Lena,Johansson Lars,Färnegårdh Katarina,Yngve Ulrika,Saleh Aljona,Haraldsson Martin,D’Hollander Agathe C. A.,Franco Marcela,Zhao Yan,Håkansson Maria,Walse Björn,Larsson Karin^ORCID,Peat Emma M.,Pelechano Vicent,Lunec John,Vojtesek Borivoj,Carmena Mar^ORCID,Earnshaw William C.,McCarthy Anna R.,Westwood Nicholas J.^ORCID,Arsenian-Henriksson Marie,Lane David P.,Bhatia Ravi,McCormack Emmet,Laín Sonia

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-03441-3.pdf

Reference38 articles.

1. Corbin, A. S. et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396–409 (2011).

2. Li, L. et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21, 266–281 (2012).

3. Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R. & Lane, D. P. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 9, 862–873 (2009).

4. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848 (2004).

5. Kranz, D. & Dobbelstein, M. Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy. Cancer Res. 66, 10274–10280 (2006).

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the Gateway: The Spatio-Temporal Dynamics of the p53 Family Driven by the Nuclear Pores and Its Implication for the Therapeutic Approach in Cancer;International Journal of Molecular Sciences;2024-07-07

2. An alternative conformation of the N-terminal loop of human dihydroorotate dehydrogenase drives binding to a potent antiproliferative agent;Acta Crystallographica Section D Structural Biology;2024-05-28

3. Bioinformatics analysis and experimental verification of the cancer-promoting effect of DHODH in clear cell renal cell carcinoma;Scientific Reports;2024-05-25

4. Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia;JCI Insight;2024-04-22

5. Discovery of Thiadiazoles as Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors by Combined Structure‐Based Modelling Methods;ChemistrySelect;2024-03-06